Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyrus R Kumana

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|April 5, 2007
Prescriptions for sustainable healthcareCyrus R Kumana
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|October 9, 2008
Aspects of general medicineCyrus R Kumana
Expert Review of Clinical Pharmacology|November 25, 2011
Raising highly desirable lipoprotein versus lowering deleterious lipoproteinBernard My Cheung, Cyrus R Kumana
BMJ (Clinical Research Ed.)|July 5, 2003
Effectiveness of lipid lowering drugs in general practice: study had two major flawsBernard M Y Cheung, Cyrus R Kumana
Frontiers in Oncology|December 15, 2022
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyondCyrus R Kumana, Yok-Lam Kwong, Harinder Gill
Drugs|July 2, 2003
Clinical role of beta-lactam/beta-lactamase inhibitor combinationsNelson Lee, Kwok-Yung Yuen, Cyrus R Kumana
Evidence-Based Medicine|June 2, 2009
Letter: viewing JUPITOR with a clear perspectiveCyrus R Kumana, Hung Fat Tse, C P Lau
Frontiers in Oncology|August 28, 2020
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to BedsideCyrus R Kumana, Raymond Mak, Yok-Lam Kwong, et al.
Pharmaceutics|September 23, 2022
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other DiseasesLynn Chin, Cyrus R Kumana, Yok-Lam Kwong, et al.
Postgraduate Medical Journal|April 24, 2017
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?Cyrus R Kumana, Kathryn C B Tan, Bernard M Y Cheung
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|April 5, 2007
Prescriptions for sustainable healthcareCyrus R Kumana
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|October 9, 2008
Aspects of general medicineCyrus R Kumana
Expert Review of Clinical Pharmacology|November 25, 2011
Raising highly desirable lipoprotein versus lowering deleterious lipoproteinBernard My Cheung, Cyrus R Kumana
BMJ (Clinical Research Ed.)|July 5, 2003
Effectiveness of lipid lowering drugs in general practice: study had two major flawsBernard M Y Cheung, Cyrus R Kumana
Frontiers in Oncology|December 15, 2022
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyondCyrus R Kumana, Yok-Lam Kwong, Harinder Gill
Drugs|July 2, 2003
Clinical role of beta-lactam/beta-lactamase inhibitor combinationsNelson Lee, Kwok-Yung Yuen, Cyrus R Kumana
Evidence-Based Medicine|June 2, 2009
Letter: viewing JUPITOR with a clear perspectiveCyrus R Kumana, Hung Fat Tse, C P Lau
Frontiers in Oncology|August 28, 2020
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to BedsideCyrus R Kumana, Raymond Mak, Yok-Lam Kwong, et al.
Pharmaceutics|September 23, 2022
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other DiseasesLynn Chin, Cyrus R Kumana, Yok-Lam Kwong, et al.
Postgraduate Medical Journal|April 24, 2017
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?Cyrus R Kumana, Kathryn C B Tan, Bernard M Y Cheung
Pageof 3